AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$CSTL

MAETZOLD DEREK J sold $76K of CSTL (indirect holdings)

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 3,622 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at $20.86 across 6 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Jun 3, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Bearish
medium confidence
Mentioned
$CSTL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could offset any short‑term pressure.

Relevance 2/10Novelty 2/10Timing: post‑market

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale by the CEO is a standard disclosure.

Company-level read

Ticker impact

$CSTLBearishMedium confidence
Context

SEC Form 4 shows CEO Derek Maetzold sold 3,622 shares for $75.5K via a 10b5‑1 plan.

Expected impact

likely modest downward pressure as market absorbs the sell‑off.

Evidence & confidence

The sale is small relative to float and executed under a pre‑arranged plan, limiting informational value.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine.

Regional

No regional effect.

Global

Negligible.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing; the stock could remain stable.

Key entities

  • Officer
    Derek J. Maetzold

    President & Chief Executive Officer of Castle Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min